[Skip to Navigation]
Ophthalmic Images
February 17, 2021

Rapid Growth of Anterior Chamber Metastasis From Presumed Non–Small Cell Lung Cancer During Targeted Therapy, Responding to a Single Intracameral Injection of Anti–Vascular Endothelial-Derived Growth Factor

Author Affiliations
  • 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong
  • 2Hong Kong Eye Hospital, Hong Kong
  • 3Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong
JAMA Ophthalmol. 2021;139(2):e204096. doi:10.1001/jamaophthalmol.2020.4096

A 57-year-old man presented with blurred vision in his right eye for 2 weeks. Examination (Figure, A) revealed a quiet eye with a well-defined whitish anterior chamber mass, with photographic documentation of serial growth compared with an examination 2 weeks previously. Despite the patient having received oral crizotinib for non–small cell lung cancer, there were new brain metastases. Excisional biopsy and chemotherapy were discussed. The use of 1.25 mg of intracameral bevacizumab led to mass shrinkage before ceritinib was administered for the new brain metastases. The lesion disappeared after 6 weeks, leaving footprints of corneal edema, and thus a biopsy was not performed (Figure, B). There was no recurrence after 4 years and no neovascular glaucoma.

Add or change institution